Since July 2017, when In the Clinic last addressed management of HIV infection, there have been meaningful improvements in our ability to prevent HIV and to manage patients living with HIV. New approaches to preexposure prophylaxis and more effective treatments have made the elimination of HIV infection a feasible goal. The federal “Ending the HIV Epidemic” initiative aims at a 90% reduction in new HIV diagnoses by 2030. This article provides updated information on how clinicians should use these improvements to manage their patients who are at risk for HIV infection or are newly diagnosed with HIV.
References
- 1.
Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. [PMID:9516219 ] CrossrefMedlineGoogle Scholar - 2. Centers for Disease Control and Prevention. HIV Surveillance Report, 2019. May 2021. Accessed at www.cdc.gov/hiv/library/reports/hiv-surveillance.html on 13 December 2021. Google Scholar
- 3. Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Updated). May 2020. Accessed at www.cdc.gov/hiv/library/reports/hiv-surveillance.html on 13 December 2021. Google Scholar
- 4.
Peters PJ ,Pontones P ,Hoover KW ,et al ;Indiana HIV Outbreak Investigation Team . HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375:229-39. [PMID:27468059 ] doi:10.1056/NEJMoa1515195 CrossrefMedlineGoogle Scholar - 5.
Branson BM ,Handsfield HH ,Lampe MA ,et al ;Centers for Disease Control and Prevention (CDC) . Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55:1-17. [PMID:16988643 ] MedlineGoogle Scholar - 6. Centers for Disease Control and Prevention. Diagnoses of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2010–2014. March 2017. Accessed at www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-2.pdf on 13 December 2021. Google Scholar
- 7. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. May 2021. Accessed at www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-26-1.pdf on 13 December 2021. Google Scholar
- 8.
Chou R ,Korthuis PT ,Huffman LH ,et al . Screening for Human Immunodeficiency Virus in Adolescents and Adults. Agency for Healthcare Research and Quality. 2005. [PMID:20722134 ] MedlineGoogle Scholar - 9.
Chou R ,Huffman L . Screening for Human Immunodeficiency Virus: Focused Update of a 2005 Systematic Evidence Review for the U.S. Preventive Services Task Force. Report no. 07-0597-1-EF. Agency for Healthcare Research and Quality. 2007. [PMID:20722143 ] MedlineGoogle Scholar - 10. Announcement: updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV—United States, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:458. [PMID:
27149423 ] doi:10.15585/mmwr.mm6517a5 CrossrefMedlineGoogle Scholar - 11.
Kuhar DT ,Henderson DK ,Struble KA ,et al ;US Public Health Service Working Group . Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34:875-92. [PMID:23917901 ] doi:10.1086/672271 CrossrefMedlineGoogle Scholar - 12. Association of Public Health Laboratories. Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm. January 2019. Accessed at www.aphl.org/aboutAPHL/publications/Documents/ID-2019Jan-HIV-Lab-Test-Suggested-Reporting-Language.pdf on 13 December 2021. Google Scholar
- 13.
Chavez P ,Wesolowski L ,Patel P ,et al . Evaluation of the performance of the Abbott ARCHITECT HIV Ag/Ab combo assay. J Clin Virol. 2011;52 Suppl 1:S51-5. [PMID:21983253 ] doi:10.1016/j.jcv.2011.09.010 CrossrefMedlineGoogle Scholar - 14.
Nasrullah M ,Wesolowski LG ,Meyer WA ,et al . Performance of a fourth-generation HIV screening assay and an alternative HIV diagnostic testing algorithm. AIDS. 2013;27:731-7. [PMID:23135170 ] doi:10.1097/QAD.0b013e32835bc535 CrossrefMedlineGoogle Scholar - 15.
Centers for Disease Control and Prevention (CDC) . False-positive oral fluid rapid HIV tests—New York City, 2005-2008. MMWR Morb Mortal Wkly Rep. 2008;57:660-5. [PMID:18566566 ] MedlineGoogle Scholar - 16.
Kleinman S ,Busch MP ,Hall L ,et al . False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation. Retrovirus Epidemiology Donor Study. JAMA. 1998;280:1080-5. [PMID:9757856 ] CrossrefMedlineGoogle Scholar - 17.
Masciotra S ,Luo W ,Youngpairoj AS ,et al . Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with specimens from HIV-1 seroconverters from the US and HIV-2 infected individuals from Ivory Coast. J Clin Virol. 2013;58 Suppl 1:e54-8. [PMID:23911678 ] doi:10.1016/j.jcv.2013.07.002 CrossrefMedlineGoogle Scholar - 18. Centers for Disease Control and Prevention. Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations. 27 June 2014. Accessed at http://dx.doi.org/10.15620/cdc.23447 on 13 December 2021. Google Scholar
- 19.
Kahn JO ,Walker BD . Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339:33-9. [PMID:9647878 ] CrossrefMedlineGoogle Scholar - 20.
Weintrob AC ,Giner J ,Menezes P ,et al . Infrequent diagnosis of primary human immunodeficiency virus infection: missed opportunities in acute care settings. Arch Intern Med. 2003;163:2097-100. [PMID:14504125 ] CrossrefMedlineGoogle Scholar - 21.
Pilcher CD ,Shugars DC ,Fiscus SA ,et al . HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS. 2001;15:837-45. [PMID:11399956 ] CrossrefMedlineGoogle Scholar - 22.
Centers for Disease Control and Prevention (CDC) . Late versus early testing of HIV—16 sites, United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2003;52:581-6. [PMID:12836626 ] MedlineGoogle Scholar - 23.
Vidrih JA ,Walensky RP ,Sax PE ,et al . Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001;111:192-4. [PMID:11530029 ] CrossrefMedlineGoogle Scholar - 24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. U.S. Department of Health and Human Services. Accessed at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/AdultandAdolescentGL_2021_08_16.pdf on 13 December 2021. Google Scholar
- 25. HHS Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Accessed at https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/Perinatal_GL.pdf on 13 December 2021. Google Scholar
- 26. Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data—United States and 6 Dependent Areas, 2019. HIV Surveillance Supplemental Report. 2021;26. Google Scholar
- 27. Centers for Disease Control and Prevention. Core indicators for monitoring the Ending the HIV Epidemic initiative (early release): National HIV Surveillance System data reported through December 2020; and preexposure prophylaxis (PrEP) data reported through September 2020. HIV Surveillance Data Tables. 2021;2. Accessed at www.cdc.gov/hiv/library/reports/hivsurveillance.html on 22 March 2022. Google Scholar
- 28. Centers for Disease Control and Prevention. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020. HIV Surveillance Special Report 27. April 2021. Accessed at www.cdc.gov/hiv/library/reports/hiv-surveillance.html on 18 April 2022. Google Scholar
- 29.
Walters SM ,Kral AH ,Simpson KA ,et al . HIV pre-exposure prophylaxis prevention awareness, willingness, and perceived barriers among people who inject drugs in Los Angeles and San Francisco, CA, 2016-2018. Subst Use Misuse. 2020;55:2409-19. [PMID:32962490 ] doi:10.1080/10826084.2020.1823419 CrossrefMedlineGoogle Scholar - 30.
Grant RM ,Lama JR ,Anderson PL ,et al ;iPrEx Study Team . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID:21091279 ] doi:10.1056/NEJMoa1011205 CrossrefMedlineGoogle Scholar - 31.
Liu AY ,Cohen SE ,Vittinghoff E ,et al . Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016;176:75-84. [PMID:26571482 ] doi:10.1001/jamainternmed.2015.4683 CrossrefMedlineGoogle Scholar - 32.
Marcus JL ,Hurley LB ,Nguyen DP ,et al . Redefining human immunodeficiency virus (HIV) preexposure prophylaxis failures [Letter]. Clin Infect Dis. 2017;65:1768-9. [PMID:29020235 ] doi:10.1093/cid/cix593 CrossrefMedlineGoogle Scholar - 33.
Volk JE ,Marcus JL ,Phengrasamy T ,et al . No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61:1601-3. [PMID:26334052 ] doi:10.1093/cid/civ778 CrossrefMedlineGoogle Scholar - 34.
McCormack S ,Dunn DT ,Desai M ,et al . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387:53-60. [PMID:26364263 ] doi:10.1016/S0140-6736(15)00056-2 CrossrefMedlineGoogle Scholar - 35. Centers for Disease Control and Prevention; U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. December 2021. Accessed at www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf on 18 April 2022. Google Scholar
- 36.
Landovitz RJ ,Donnell D ,Clement ME ,et al ;HPTN 083 Study Team . Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385:595-608. [PMID:34379922 ] doi:10.1056/NEJMoa2101016 CrossrefMedlineGoogle Scholar - 37. Marzinke MA, Delany-Moretlwe S, Agyei Y, et al; HPTN 084 study team. Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084. Presented at the 11th IAS Conference on HIV Science, 18–21 July 2021. Google Scholar
- 38. HIV Prevention Trials Network. HPTN 084 Study Demonstrates Superiority of Injectable Cabotegravir to Oral FTC/TDF for the Prevention of HIV in Cisgender Women in Sub-Saharan Africa [News release]. 9 November 2020. Accessed at www.hptn.org/news-and-events/announcements/hptn-084-study-demonstrates-superiority-of-injectable-cabotegravir-to on 13 December 2021. Google Scholar
- 39. Association of Public Health Laboratories. Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm. April 2017. Accessed at www.aphl.org/aboutAPHL/publications/Documents/ID_2017Apr-HIV-Lab-Test-Suggested-Reporting-Language.pdf on 13 December 2021. Google Scholar
- 40.
Baeten JM ,Palanee-Phillips T ,Brown ER ,et al ;MTN-020-ASPIRE Study Team . Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121-32. [PMID:26900902 ] CrossrefMedlineGoogle Scholar - 41.
Nel A ,van Niekerk N ,Kapiga S ,et al ;Ring Study Team . Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133-43. [PMID:27959766 ] CrossrefMedlineGoogle Scholar - 42. Cunningham D, Molina JM, Yazdanpanah Y, et al. Islatravir safety analysis through week 96 from a phase 2 trial in treatment naive adults with HIV-1 infection. J Int AIDS Soc. 2021;24:22. Google Scholar
- 43. Matthews RP, Zang X, Barrett S, et al. Next-generation islatravir implants projected to provide yearly HIV prophylaxis [Abstract]. Presented at the Conference on Retroviruses and Opportunistic Infections, 6–10 March 2021. Abstract no. 88. Google Scholar
- 44.
Liu Y ,Cao W ,Sun M ,et al . Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. Emerg Microbes Infect. 2020;9:194-206. [PMID:31985356 ] doi:10.1080/22221751.2020.1713707 CrossrefMedlineGoogle Scholar - 45. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Updated 11 June 2021. Accessed at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines on 13 December 2021. Google Scholar
- 46.
Castilla J ,Del Romero J ,Hernando V ,et al . Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101. [PMID:16123689 ] CrossrefMedlineGoogle Scholar - 47.
Cohen MS ,Chen YQ ,McCauley M ,et al ;HPTN 052 Study Team . Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830-9. [PMID:27424812 ] doi:10.1056/NEJMoa1600693 CrossrefMedlineGoogle Scholar - 48.
Lundgren JD ,Babiker AG ,Gordin F ,et al ;INSIGHT START Study Group . Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807. [PMID:26192873 ] doi:10.1056/NEJMoa1506816 CrossrefMedlineGoogle Scholar - 49.
Lee PK ,Kieffer TL ,Siliciano RF ,et al . HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother. 2006;57:803-5. [PMID:16533823 ] CrossrefMedlineGoogle Scholar - 50.
Nettles RE ,Kieffer TL ,Kwon P ,et al . Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA. 2005;293:817-29. [PMID:15713771 ] CrossrefMedlineGoogle Scholar - 51. World Health Organization. HIV drug resistance report 2012. 1 July 2012. Accessed at www.who.int/publications/i/item/9789241503938 on 13 December 2021. Google Scholar
- 52.
Cohen MS ,Chen YQ ,McCauley M ,et al ;HPTN 052 Study Team . Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375:830-9. [PMID:27424812 ] doi:10.1056/NEJMoa1600693 CrossrefMedlineGoogle Scholar - 53.
Thompson MA ,Horberg MA ,Agwu AL ,et al . Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2021;73:e3572-e3605. [PMID:33225349 ] doi:10.1093/cid/ciaa1391 CrossrefMedlineGoogle Scholar - 54.
Lewden C ,Chene G ,Morlat P ,et al ;Agence Nationale de Recherches sur le Sida et les Hepatites Virales (ANRS) CO8 APROCO-COPILOTE Study Group . HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007;46:72-7. [PMID:17621240 ] CrossrefMedlineGoogle Scholar - 55.
Zolopa A ,Andersen J ,Powderly W ,et al . Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009;4:e5575. [PMID:19440326 ] doi:10.1371/journal.pone.0005575 CrossrefMedlineGoogle Scholar - 56.
Alade RO ,Vragovic O ,Duffy C ,et al . Human papillomavirus co-testing results effectively triage normal cervical cytology in HIV-positive women aged 30 years and older. J Low Genit Tract Dis. 2017;21:125-8. [PMID:28257290 ] doi:10.1097/LGT.0000000000000304 CrossrefMedlineGoogle Scholar - 57.
Castle PE ,Fetterman B ,Poitras N ,et al . Safety against cervical precancer and cancer following negative human papillomavirus and Papanicolaou test results in human immunodeficiency virus-infected women. Arch Intern Med. 2012;172:1041-3. [PMID:22641193 ] doi:10.1001/archinternmed.2012.1744 CrossrefMedlineGoogle Scholar - 58.
Thea DM ,Steketee RW ,Pliner V ,et al . The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS. 1997;11:437-44. [PMID:9084790 ] CrossrefMedlineGoogle Scholar - 59. New York State Department of Health AIDS Institute. HIVQUAL Workbook: Guide for Quality Improvement in HIV Care. New York HIV/AIDS Bureau, Health Resources and Services Administration; 2006. Google Scholar
- 60. Hardy WD. Fundamentals of HIV Medicine 2021. Oxford Univ Pr; 2021. Google Scholar
Author, Article, and Disclosure Information
Affiliations:
West Virginia University School of Medicine, Morgantown, West Virginia
University of Utah School of Medicine, Salt Lake City, Utah
CME Objective: To review current evidence for screening, prevention, initial evaluation, antiretroviral therapy, other management strategies, and practice improvement of HIV infection.
Funding Source: American College of Physicians.
Disclosures: Dr. Feinberg, ACP Contributing Author, reports a research contract from Gilead Sciences, consulting fees from Gilead Sciences and ViiV Healthcare, payment for expert testimony from Motley Rice LLC, and leadership roles in the HIV Medicine Association. Dr. Keeshin, ACP Contributing Author, reports no disclosures of interest. All relevant financial relationships have been mitigated. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-0039.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Stephanie Chang, MD, MPH, Deputy Editor, reports employment with the Agency for Healthcare Research and Quality, travel compensation from the Guidelines International Network, and participation in the Patient-Centered Outcomes Research Institute methodology committee. Vineet Chopra, MD, MSc, Deputy Editor, reports grants received from the Agency for Healthcare Research and Quality and royalties from UpToDate and Oxford University Press. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interests to disclose. Eliseo Guallar, MD, MPH, DrPH, Deputy Editor, Statistics, reports that he is employed at Johns Hopkins University. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center and consultancy with Boston Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports employment with the Perelman School of Medicine, University of Pennsylvania, and consultancies with the U.S. Food and Drug Administration and the State of Colorado.
With the assistance of additional physician writers, the editors of Annals of Internal Medicine develop In the Clinic using MKSAP and other resources of the American College of Physicians. The patient information page was written by Julia Thayer from the Center for Quality at the American College of Physicians.
In the Clinic does not necessarily represent official ACP clinical policy. For ACP clinical guidelines, please go to https://www.acponline.org/clinical_information/guidelines/.
This article was published at Annals.org on 14 June 2022.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.